Hi friend,

Another busy week in mental health.

Neurosterix raised $105M for its schizophrenia treatment; Triplemoon raised a $4M seed extension; and Spring Health launched a new marketplace (fascinating).

The news was popping in psychedelics too. Delix raised $100M; FDA reportedly shelved its fast-track drug review programme; and Helus Pharma's psychedelic-inspired depression treatment met its primary endpoint in a Phase 3 trial. What’s wild is that this isn’t even all the major psychedelics news this week.

On the research front, an RCT found that an AI maternal-health chatbot did not reduce anxiety or depression; trauma-focused therapies were found to reduce PTSD symptoms in people with psychosis; and a new report from Mind called for greater emphasis on relationships and belonging in mental-health policy.

Lots to cover, so let’s get into it.

What happened in mental health last week?

Industry News:

⏺️ Neurosterix raised $105M to advance a new schizophrenia treatment into Phase 2 trials. The Swiss neuroscience company secured Series B funding led by RTW Investments to develop NTX-253, an oral drug targeting the brain's muscarinic M4 receptor. Unlike conventional antipsychotics that directly block dopamine receptors, NTX-253 is designed to influence dopamine signalling indirectly. The approach follows growing interest in muscarinic treatments after the approval of Cobenfy in 2024. (link)

⏺️ Delix Therapeutics raised $100M to advance a non-hallucinogenic psychedelic-inspired drug. The company closed a Series C round to fund Phase 2 development of zalsupindole and expand its broader neuroscience pipeline. Delix is developing compounds designed to promote changes in brain connectivity associated with psychedelic treatments without producing hallucinations — which is one of the major challenges for clinical and regulatory adoption. (link)

⏺️ Triplemoon raised a $4M seed extension to bring virtual mental-health support into more paediatric practices. The Dallas startup secured an extension to its seed funding, bringing the total to $7.5M. Triplemoon works with primary-care and paediatric practices to connect children with behavioural-health coaches through virtual appointments, including support for anxiety, ADHD and eating disorders. The company says it works with nearly 100 primary-care doctors across several US states and Washington, DC, and plans to use the funding to expand its clinic partnerships and technology. (link)

⏺️ Czech mental health business Hedepy secured €4M in venture debt to expand its European mental-health services. The financing, provided by Orbit Capital, will be used to make strategic acquisitions and broaden the company’s clinical services. Originally an online psychotherapy platform, Hedepy has expanded into in-person care and technology for clinicians. It now operates across nine European countries. (link)

⏺️ Elomia Health acquired AI mental-wellbeing companion Earkick. Earkick provides an AI companion for emotional support and tracking patterns in mood, sleep and daily habits. It reports having more than 250,000 users. Financial terms were not disclosed. (link)

⏺️ Huntsman Mental Health Institute received a $35M donation for a new research building. Gail Miller and the Larry H. & Gail Miller Family Foundation made the donation through the Huntsman Mental Health Foundation. The new University of Utah building will bring researchers and clinicians together to accelerate the translation of scientific discoveries into patient care. The project previously received $90M in state funding, while the institute itself was established following a $150M Huntsman family donation in 2019. (link)

⏺️ FDA reportedly shelved its fast-track drug review programme, raising uncertainty for psychedelic treatments. Reuters reported that the US Food and Drug Administration has effectively stopped advancing its Commissioner's National Priority Voucher programme, which was designed to shorten reviews of selected drugs from around 10 months to as little as one or two months. The programme had awarded vouchers to 22 treatments, including psychedelic candidates from Compass Pathways, Usona Institute and Transcend Therapeutics. According to Reuters, no new vouchers have been issued since the former FDA commissioner departed in May, although the Department of Health and Human Services maintains that the pilot remains active. Existing applications are still being reviewed, but the potential impact on approval timelines remains unclear. (link)

⏺️ US government committed up to $4.9M to advance ibogaine development and opened a $20M psychedelic research funding opportunity. The Department of Health and Human Services announced funding through ARPA-H to prepare ibogaine for potential clinical trials in PTSD. Mark Cuban's Cost Plus Drug Company received an award of up to $4.2M to develop the manufacturing and regulatory processes, while Beond received up to $800,000 to provide clinical data. Separately, the NIMH opened a $20M funding opportunity for a research network studying rapid-acting psychiatric treatments, including ketamine and psilocybin. (link)

⏺️ Johnson & Johnson's Caplyta succeeded in a second Phase 3 trial for bipolar mania. In a three-week randomised trial, adults receiving Caplyta experienced a 3.7-point greater reduction in manic symptoms than those receiving placebo. A clinically defined response was achieved by 43.9% of patients taking Caplyta, compared with 23.7% receiving placebo. Improvements were reported as early as day three. The results support a planned FDA application to expand the drug's approved uses; Caplyta is already authorised for bipolar depression, but not bipolar mania. (link)

⏺️ Helus Pharma's psychedelic-inspired depression treatment met its primary endpoint in a Phase 3 trial. The company, formerly Cybin, reported positive results for HLP003, a modified form of psilocin, in a randomised trial involving 222 adults with moderate to severe depression. After six weeks, depression scores fell by 19.5 points among those receiving HLP003, compared with 11.9 points for placebo. Remission rates were 50.9% versus 18.2%, with significant benefits maintained through 12 weeks. (link)

⏺️ Spring Health launched a marketplace for digital mental-health and wellbeing programmes. OK, this is SUPER interesting. Spring has launched a “Care Marketplace”, which allows eligible members to access third-party mental health and wellbeing apps from companies like Big Health and Mightier. Members can exchange their Spring therapy session credits for annual access to these apps. Spring says its matching algorithm will recommend the appropriate level of care for members. This move is likely a reaction to employers and payers requiring providers to better match interventions to the right level of need for their members. This is potentially an interesting new route to market for digital interventions and also a fascinating play by Spring to establish itself as a true platform in mental health. (link)

⏺️ Spring Health also published a proposed legislative framework for regulating AI chatbots used for mental-health support. The mental-health provider developed the Safety Assessments, Frontline Escalation, and Mental-Health Accountability for AI (SAFE-MH AI) Act as a model for discussion with policymakers and industry stakeholders. It calls for independent clinical and technical safety assessments, pathways to human care during mental-health crises and regulatory accountability when safeguards fail. (link)

⏺️ Odyssey Behavioral Healthcare launched virtual intensive outpatient treatment for adults. The US provider introduced Odyssey Virtual, offering live, clinician-led mental-health treatment four days a week, with afternoon and evening sessions. The programme is designed for people needing more support than weekly therapy without entering residential care. It initially serves adults in Florida, North Carolina, Ohio and Virginia, treating conditions including depression, anxiety, bipolar disorder and PTSD. (link)

⏺️ Willow Health launched same-day virtual mental-health urgent care in North Carolina. Working with Alliance Health and Johnston County, Willow is offering adults aged 18 and over rapid access to psychiatric assessments, therapy, medication management and peer support. The partnership aims to provide an alternative to long waits for outpatient care and potentially avoidable emergency department visits. (link)

⏺️ Osmind launched AI tools for specialist psychiatry practices. The company introduced Osmind Intelligence, integrating AI into its software for practices delivering treatments such as ketamine and brain stimulation. The tools are intended to help clinicians manage the administrative and clinical workflows associated with specialist psychiatric care. Osmind says its platform supports more than 1,000 practices that have delivered approximately one million treatments. (link)

⏺️ mdhub expanded into electronic health records, patient management and billing. The behavioural-health software company launched three new products: a new EHR, CRM and RCM tool. Don’t you just love software acronyms? (link)

⏺️ Apple launched a US study examining how people use AI for health advice. Working with OpenEvidence, Apple introduced the Health AI Usage Study to investigate how people interact with conversational AI tools about their health. Researchers will examine trust, understanding, response quality and whether AI-generated information influences everyday health decisions. (link)

Join our Session on the most recent RCT on AI Mental Health Support

This Thursday, Xuan Zhao and Julie Cachia are hosting a Hemingway Session to walk us through the findings from their recent RCT — one that followed 1,137 university students over six weeks as they used Flourish Science’s AI app. We’ll also be discussing what they learned about trial design for AI products and their thoughts on building research roadmaps for AI mental health interventions. FYI, Hemingway Sessions are for Hemingway Pro Members only.

Research News:

⏺️ AI maternal-health chatbot did not reduce anxiety or depression in a randomised trial of 400 participants. Researchers tested whether access to a generative AI chatbot improved outcomes among pregnant and postpartum people from racial and ethnic minority groups in the US. After 12 months, participants offered the chatbot had no significant improvement in anxiety or depression compared with a control group receiving monthly children's books. The intervention also showed no clear benefit for most other maternal-health outcomes. Exploratory analyses found that greater chatbot engagement was associated with higher anxiety scores, although this does not establish that chatbot use caused anxiety. (link)

⏺️ Study of 41 AI models found mental-health recommendations varied depending on the user. Researchers tested how large language models responded to identical clinical scenarios presented by a clinician, caregiver or patient. Across 19 scenarios, they collected more than 35,000 responses and analysed the interventions recommended. Models often gave clinicians more consultation-style answers while offering patients and caregivers simpler, more qualified advice. Some recommendations also differed from the models' own ratings of treatment options. The findings come from a preprint and assess simulated responses. (link)

⏺️ Three antidepressants outperformed Prozac in sustaining depression improvement, major review found. A systematic review and network meta-analysis published in The Lancet Psychiatry examined 115 randomised trials involving more than 30,000 adults with depression. Its primary analysis, covering 35 trials and 9,888 participants, found that escitalopram, duloxetine and agomelatine were more effective than fluoxetine (Prozac) at achieving and maintaining a treatment response over periods longer than 12 weeks. Escitalopram and duloxetine also had lower treatment discontinuation rates. However, 54% of studies in the primary analysis were judged at high risk of bias, limiting confidence in the comparisons. The researchers called for more direct trials comparing antidepressants' long-term effectiveness. (link)

⏺️ Trauma-focused therapies reduced PTSD symptoms in people with psychosis. A multicentre randomised trial assigned 162 people with PTSD and a history of schizophrenia-spectrum psychosis to prolonged exposure therapy, eye movement desensitisation and reprocessing (EMDR), cognitive restructuring or a waiting-list control. All three therapies produced significantly greater reductions in PTSD symptoms over six months, with large effects compared with the control group. However, the treatments did not significantly improve psychosis symptoms. The findings support making trauma-focused treatment more accessible to people with psychosis, although larger trials are needed. (link)

⏺️ Brief psychotherapy produced mixed results for anxiety during pregnancy. A randomised trial involving 234 pregnant women with elevated depressive symptoms compared brief interpersonal psychotherapy with enhanced usual care. Although women receiving psychotherapy reported significantly lower anxiety scores at several follow-up assessments, including a 5.2-point difference at the end of pregnancy, the difference in overall anxiety trajectories was not statistically significant. There was also no significant difference in rates of diagnosed generalised anxiety disorder at the end of pregnancy. The findings suggest possible benefits for anxiety symptoms, but do not provide conclusive evidence that the intervention was more effective than enhanced usual care. (link)

⏺️ UK research called for greater emphasis on relationships and belonging in mental-health policy. A study led by Mind Organisations drew on the experiences of 220 Londoners to examine the social conditions shaping mental health. Participants described how financial insecurity, housing pressures, loneliness and fragmented services contributed to distress, often long before a crisis. The report calls for earlier, more accessible support rooted in communities and relationships. It comes as a timely reminder for UK policymakers ahead of the soon-to-be-announced new mental health strategy. (link)

That’s all for this week.

Keep fighting the good fight!

Steve Duke

Founder of Hemingway

P.S. If you find these updates valuable, consider becoming a Hemingway Pro Member.

Keep reading